Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant

Fineline Cube Jun 18, 2026
Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 19.0 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Hopstem Biotechnology Secures FDA Clearance for hNPC01 Neural Progenitor Cell Therapy in Hemorrhagic Stroke Motor Dysfunction

Fineline Cube Jun 18, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Deals

Sanyou Biopharmaceuticals & Yugong Biotech Forge Strategic Enzyme Development Alliance

Fineline Cube Nov 11, 2025

Sanyou Biopharmaceuticals Co., Ltd. and Yugong Biotech Co., Ltd. today signed a strategic cooperation agreement...

Company Drug

Grand Pharmaceutical & Glenmark Specialty Secure China NMPA Approval for Ryaltris Nasal Spray

Fineline Cube Nov 11, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) together with Glenmark Specialty S.A. announced that the Ryaltris...

Company Drug

Lepu Biopharma Secures FDA IND Clearance for CDH17‑Targeted ADC MRG007

Fineline Cube Nov 11, 2025

Lepu Biopharma Co., Ltd. (HKG: 2157) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug

Novartis Wins FDA Approval for Remibrutinib Tablets – First BTK Inhibitor for Chronic Spontaneous Urticaria

Fineline Cube Nov 11, 2025

Novartis AG (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has granted...

Company Deals

Lyell Immunopharma Secures Global Rights to LYL273 CAR‑T Therapy – Major Step Toward mCRC Treatment

Fineline Cube Nov 11, 2025

Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative...

Company Drug

DualityBio Secures FDA Fast‑Track Designation for EGFR/HER3 Bispecific ADC AVZO‑1418

Fineline Cube Nov 11, 2025

Duality Biotherapeutics, Inc. (DualityBio, HKG: 9606) announced that its co‑developed EGFR/HER3 bispecific antibody‑drug conjugate (ADC),...

Others

Mabwell Partners with Ping An Health to Launch Integrated Bone‑Health & Autoimmune Care Platform

Fineline Cube Nov 11, 2025

Mabwell Bioscience (SHA: 688062) disclosed a strategic, deep‑level collaboration with Ping An Healthcare and Technology...

Company Drug

Roche Announces Positive Phase III Results for Fenebrutinib in Relapsing & Primary‑Progressive Multiple Sclerosis

Fineline Cube Nov 11, 2025

Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) reported that both pivotal Phase III trials of its...

Company Drug

Simcere Launches Phase II Trial of T‑Reg‑Selective IL‑2 Fusion (SIM0278) for Moderate‑to‑Severe Atopic Dermatitis in China

Fineline Cube Nov 11, 2025

Simcere Pharmaceutical Group Ltd. (HKG: 2096) announced that the Phase II clinical study of its proprietary...

Company Medical Device

Gaush Meditech’s Subsidiary Secures China Registration for Integrated Ophthalmic Electrophysiology System

Fineline Cube Nov 11, 2025

Gaush Meditech Ltd. (HKG: 2407) announced that its wholly‑owned subsidiary Gaush Tech Ltd. has been issued...

Company Deals

Brise Pharma Closes RMB 200 M Series A to Fund Pivotal Phase III Trial of First‑in‑Class CGRP Small‑Molecule Analgesic BR005

Fineline Cube Nov 11, 2025

Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of...

Company Drug

Mabwell’s 9MW3811 Gains NMPA Approval to Launch World‑First IL‑11‑Targeting Phase 2 Trial for Pathological Scarring

Fineline Cube Nov 11, 2025

Mabwell Bioscience (SHA: 688062) announced that its proprietary monoclonal antibody 9MW3811 has received clearance from...

Company Deals

MeiraGTx Grants Eli Lilly Worldwide Rights to AAV‑AIPL1 Gene Therapy for LCA4

Fineline Cube Nov 11, 2025

MeiraGTx Holdings plc (NASDAQ: MGTX) announced a strategic ophthalmology collaboration with Eli Lilly and Company...

Company Drug

Innovent Biologics & Sanegene Bio USA Report First‑in‑Human Success for IBI3016 siRNA Hypertension Therapy

Fineline Cube Nov 11, 2025

Innovent Biologics, Inc. (HKG: 1801) and Sanegene Bio USA Inc. announced today the first‑in‑human (FIH)...

Company Drug

Hangzhou Bio‑Sincerity Secures NMPA Approval for BIOS‑0625 Tablet – First‑in‑Class Ulcerative Colitis Therapy

Fineline Cube Nov 11, 2025

Hangzhou Bio‑Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS‑0625 tablet, a Class 1 small‑molecule...

Company Deals

CanSinoBIO Licenses ISL‑3C‑LNP Platform to PanRu Biotech – $100 M+ Deal to Accelerate mRNA Cancer Vaccines

Fineline Cube Nov 11, 2025

CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co.,...

Company Deals

Eisai China and Beckman Coulter Launch Alzheimer’s Blood‑Test Collaboration in Mainland China

Fineline Cube Nov 10, 2025

Eisai China Holdings (TYO: 4523) and Beckman Coulter Laboratory Systems (Suzhou) Co., Ltd. today signed...

Company Drug

Gilead Sciences’ Tro Delvy Fails to Meet Primary Endpoint in ASCENT‑07 Metastatic Breast Cancer Trial

Fineline Cube Nov 10, 2025

Gilead Sciences Inc. (NASDAQ: GILD) today disclosed that the Phase III ASCENT‑07 study, which compared Trodelvy...

Company Deals

Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance

Fineline Cube Nov 10, 2025

Insilico Medicine, a leader in artificial‑intelligence‑powered drug discovery, today announced a strategic collaboration with Eli Lilly (NYSE:...

Company Deals

SanegeneBio & Eli Lilly Sign Global Partnership to Advance RNAi Therapies for Metabolic Diseases

Fineline Cube Nov 10, 2025

SanegeneBio, a biotechnology company specializing in RNAi therapeutics, today announced a global research collaboration and...

Posts pagination

1 … 100 101 102 … 685

Recent updates

  • Hopstem Biotechnology Secures FDA Clearance for hNPC01 Neural Progenitor Cell Therapy in Hemorrhagic Stroke Motor Dysfunction
  • Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant
  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hopstem Biotechnology Secures FDA Clearance for hNPC01 Neural Progenitor Cell Therapy in Hemorrhagic Stroke Motor Dysfunction

Company Deals

Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.